Neuroscience
We are driven by our vision of leading the precision neuroscience revolution to reduce the burden and disability caused by serious nervous system disorders. For more than 60 years, our goal has been to deliver breakthrough, outcome-improving solutions in areas of critical unmet need for people with neuropsychiatric, neurodegenerative and autoantibody-driven diseases. Our strategy harnesses scientific advances across human genetics, data science, biomarkers and digital therapeutics to reconceptualize how we diagnose and treat targeted disorders of the nervous system, utilizing precision approaches.
We are building a world-class pipeline driven by innovation that we hope will lead to transformative therapies for a diverse population of patients with neuropsychiatric, neurodegenerative and neurological disorders.
Through scientific advancements, a broad range of expertise, and strategic partnerships, we aim to fundamentally change how these disorders are treated and make a real difference, not just for patients, but also for society.
We are determined to continue to increase our understanding of nervous system disorders by supporting and engaging with patients, through open dialogue and innovative treatments.
We are building a world-class pipeline driven by innovation that we hope will lead to transformative therapies for a diverse population of patients with neuropsychiatric, neurodegenerative and neurological disorders.
Through scientific advancements, a broad range of expertise, and strategic partnerships, we aim to fundamentally change how these disorders are treated and make a real difference, not just for patients, but also for society.
We are determined to continue to increase our understanding of nervous system disorders by supporting and engaging with patients, through open dialogue and innovative treatments.
Holding patients and caregivers at our core
Our ultimate responsibility remains to our patients who, alongside caregivers, are at the heart of everthing we do.
We cannot look at neuroscience through the lens of science alone. Each person’s experience of a nervous system disease is uniquely influenced by personal, medical, environmental and social factors. It is essential to work in partnership with the patient community to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.
This is why we work with around 30 patient and carer organisations across Europe to enhance our understanding of living with nervous system diseases. We are part of a broadly-based healthcare company, with a decentralised structure which assures that we remain focused on the markets in every therapeutic and geographical area that we serve.
We cannot look at neuroscience through the lens of science alone. Each person’s experience of a nervous system disease is uniquely influenced by personal, medical, environmental and social factors. It is essential to work in partnership with the patient community to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.
This is why we work with around 30 patient and carer organisations across Europe to enhance our understanding of living with nervous system diseases. We are part of a broadly-based healthcare company, with a decentralised structure which assures that we remain focused on the markets in every therapeutic and geographical area that we serve.
Leading the way through innovation
Our medications and innovations have helped improve the quality of care for millions of people living with neuropsychiatric conditions.
Today, we are committed to maintaining innovative Research and Development (R&D) that solves for unmet needs across nervous system disorders.
Today, we are committed to maintaining innovative Research and Development (R&D) that solves for unmet needs across nervous system disorders.
Our treatment areas
-
Neuropsychiatric Disorders
We are expanding our focus to include the full range of psychosis spectrum disorders and mood dysregulation. -
Neurodegenerative Disorders
We are utilising biomarker sciences to drive disease understanding, patient identification and accelerated development.
Our extensive research and innovations aim to improve the quality of care for millions of people with neurological conditions. We’ve equipped ourselves with the knowledge, tools and technology to expand our focus into the full range of psychosis spectrum disorders and mood dysregulation, and by leveraging shared pathology across disease areas to broaden therapeutic opportunities and develop innovations for populations with high unmet needs - such as, for instance in neurodegenerative and neurological disorders. We’re motivated by making a real difference for not just patients, but for society as a whole.
Dr. Tamara Werner-Kiechle
EMEA THERAPEUTIC AREA LEAD, CENTRAL NERVOUS SYSTEM & PULMONARY HYPERTENSION
©Janssen-Cilag NV/B.V., a Johnson&Johnson company – CP-490858 – Approval date: 11-2024, vu/er Luc Van Oevelen, Antwerpseweg 15-17, 2340 Beerse